NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

antibody

MARK Pan Polyclonal Antibody

PA5-36396

100 uL

US 481.00

polyclonal

domestic rabbit

nonconjugated

human, mouse, rat

immunohistochemistry, immunocytochemistry, immunohistochemistry - paraffin section

MARK Pan Polyclonal Antibody

PA5-36396

100 uL

US 481.00

Polyclonal

Antigen affinity chromatography

Rabbit

Human, Mouse, Rat

Immunocytochemistry: 1:50-1:200, Immunohistochemistry (Paraffin): 1:50-1:200

Human, Mouse, Rat

IgG

Store at 4 C short term. For long term storage, store at -20 C, avoiding freeze/thaw cycles.

MARK1 (MAP/microtubule affinity-regulating kinase 1) belongs to the MARK family of serine/threonine kinases. MARK family protein kinases phosphorylate microtubule-associated proteins and may play a role in cytoskeletal stability. MARK2 refers to MAP/microtubule affinity-regulating kinase 2 isoform a [Homo sapiens]. EMK (ELKL Motif Kinase) is a small family of ser/thr protein kinases involved in the control of cell polarity, microtubule stability and cancer. Several cDNA clones have been isolated that encoded two isoforms of the human ser/thr protein kinase EMK1 called MARK2. MARK3 was originally identified as a marker that was induced by treatment with DNA damaging agents, and loss of MARK3 was found with carcinogenesis in the pancreas. MARK4 contains an N terminal serine/threonine kinase domain, a central ubiquitin associated domain, and a C terminal KA1 associated kinase domain. RT PCR analysis detects upregulated expression of the gene for MARK4 in nearly all clinical hepatocellular carcinoma cells.

Synthetic peptide corresponding to amino acids 180-230 of human MARK1

Liquid

Immunocytochemistry: 1:50-1:200, Immunohistochemistry (Paraffin): 1:50-1:200

1600015G02Rik; 2410090P21Rik; A430080F22Rik; AW491150; B930025N23Rik; C79806; Cdc25C-associated protein kinase 1; cTAK1; C-TAK1; ELKL motif kinase 1; ELKL motif kinase 2; ELKL motif serine/threonine-protein kinase 3; ELKL motif serine-threonine protein kinase 3; Emk; EMK1; EMK-1; Emk2; EMK-2; EMK2/MARK3 serine-threonine protein kinase; Emk3; ETK1; ETK-1; KIAA1477; Kiaa1860; KP78; MAP/microtubule affinity regulating kinase 1; MAP/microtubule affinity regulating kinase 2; MAP/microtubule affinity regulating kinase 3; MAP/microtubule affinity regulating kinase 4; MAP/microtubule affinity-regulating kinase 1; MAP/microtubule affinity-regulating kinase 2; MAP/microtubule affinity-regulating kinase 3; MAP/microtubule affinity-regulating kinase 4; MAP/microtubule affinity-regulating kinase 4L; MAP/microtubule affinity-regulating kinase like 1; MAP/microtubule affinity-regulating kinase-like 1; MARK; MARK1; mark1 {ECO:0000312; MARK2; mark2 {ECO:0000312; MARK3; MARK4; MARK4 serine/threonine protein kinase; MARK4L; MARK4S; MARKL1; MARKL1L; microtubule affinity regulating kinase 1; microtubule affinity regulating kinase 2; microtubule affinity regulating kinase 3; microtubule affinity regulating kinase 4; mKIAA1477; mPar-1c; MPK10; MPK-10; Par-1; PAR1 homolog; PAR1 homolog b; PAR1 homolog c; PAR1A; Par-1a; Par1b; Par-1b; Par1c; Par-1c; PAR-1D; protein kinase STK10; RGD:619882}; RGD:708483}; Ser/Thr protein kinase PAR-1; Ser/Thr protein kinase PAR-1B; serine/threonine kinase; serine/threonine protein kinase EMK; serine/threonine-protein kinase MARK1; Serine/threonine-protein kinase MARK2; serine/threonine-protein kinase p78; testicular tissue protein Li 117